<DOC>
	<DOCNO>NCT02100696</DOCNO>
	<brief_summary>This phase III , double blind , placebo-controlled , multicenter study investigate efficacy safety etrolizumab induction maintenance remission participant moderately severely active ulcerative colitis ( UC ) refractory intolerant TNF inhibitor .</brief_summary>
	<brief_title>A Study Efficacy Safety Etrolizumab Ulcerative Colitis Participants Who Are Refractory Intolerant Tumor Necrosis Factor ( TNF ) Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Moderately severely active UC determine Mayo Clinic Score assessment ( MCS ) Intolerance , loss response failure respond treatment least one TNFinhibitor within previous 5 year Washout antiTNF therapy least 8 week precede Day 1 Background regimen UC may include oral 5aminosalicylic acid ( 5ASA ) , oral corticosteroid , budesonide multimatrix system ( MMX ) , probiotic , azathioprine ( AZA ) , 6mercaptopurine ( 6MP ) , methotrexate ( MTX ) dose stable screen period Use highly effective contraception define protocol Must receive colonoscopy within past year willing undergo colonoscopy lieu flexible sigmoidoscopy screen A history current condition disease affect digestive tract , indeterminate colitis , Crohn 's disease , fistulas abdominal abscess , colonic mucosal dysplasia , intestinal obstruction , toxic megacolon , unremoved adenomatous colonic polyp Prior plan surgery UC Past present ileostomy colostomy Any prior treatment etrolizumab antiintegrin agent ( include natalizumab , vedolizumab , efalizumab ) rituximab Chronic hepatitis B C infection , human immunodeficiency virus ( HIV ) tuberculosis Evidence treatment Clostridium difficile clinically significant cytomegalovirus ( CMV ) colitis within 60 day prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>